A case report on wegener’s granulomatosis


  • Bipin Shaji Department of Pharmacy Practice, Karavali College of Pharmacy, Mangalore, Karnataka, India
  • Abisri Suresh Department of Pharmacy Practice, Karavali College of Pharmacy, Mangalore, Karnataka, India




Wegener’s granulomatosis, Monoclonal antibodies, Corticosteroids, Human leukocyte antigen, Glomerulonephritis


Wegener’s Granulomatosis, also known as granulomatosis with polyangiitis, is a rare multisystem autoimmune disease with an unknown etiology that can affect persons of all ages. In most cases, the condition affects the respiratory tract and the kidneys. The initial symptoms include a runny nose (rhinorrhea), nasal crusting, and nasal blockage or congestion. More significant symptoms include nose bleeds, ulcerations of the nasal mucous membranes with subsequent bacterial infection, sinus discomfort, sinus inflammation, and hoarseness. The patient was presented with symptoms like reddish staining of the eyes, hearing loss, and numerous joint discomfort and swelling of the lower limbs. The antineutrophil cytoplasmic antibody, cytoplasmic (C-ANCA), and human leukocyte antigen- B27 (HLA-B27) were both positive, and renal biopsy revealed necrotizing and crescentic glomerulonephritis. The treatment was initiated with corticosteroids and monoclonal antibodies. The patient responded positively to the therapy, and her health appears to be improving.


Kubaisi B, Samra KA, Foster CS. Granulomatosis with polyangiitis (Wegener's disease): An updated review of ocular disease manifestations. Intractable & rare diseases research. 2016.

Gross WL, Trabandt A, Csernok E. Pathogenesis of Wegener's granulomatosis. InAnnales de Medecine Interne 1998;149(5):280-6.

Watts RA, Scott DG. L32. ANCA vasculitis over the world. What do we learn from country differences?. Presse medicale (Paris, France: 1983). 2013;42(4):591-3.

Regan MJ, Hellmann DB, Stone JH. Treatment of Wegener's Granulomatosis. Rheumatic Disease Clinics. 2001;27(4):863-86.

Singer O, McCune WJ. Update on maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. Current opinion in rheumatology. 2017;29(3):248-53.

Langford CA. Update on the treatment of granulomatosis with polyangiitis (Wegener’s). Current treatment options in cardiovascular medicine. 2012;14(2):164-76.

Davani-Davari D, Karimzadeh I, Khalili H. The potential effects of anabolic-androgenic steroids and growth hormone as commonly used sport supplements on the kidney: a systematic review. BMC nephrology. 2019;20(1):1-2.

Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy, Asthma & Clinical Immunology. 2013;9(1):1-25.

Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. InMayo Clinic Proceedings. 2006;81(10):1361-7.

Ramsey MK, Owens D. Wegener’s Granulomatosis: A review of the clinical implications, diagnosis, and treatment. Laboratory Medicine. 2006;37(2):114-6.




How to Cite

Shaji, B., & Suresh, A. (2022). A case report on wegener’s granulomatosis. International Journal of Basic & Clinical Pharmacology, 11(4), 344–347. https://doi.org/10.18203/2319-2003.ijbcp20221602



Case Reports